Second episode of the new webinar series on Career Development launched by the VPHi Young Scientists Committee.
"Exploring the Future: Entrepreneurship in In Silico Medicine” is the second episode of the new webinar series on Career Development launched by the VPHi Young Scientists Committee.
The webinar was held online on December 12, 10:30 - 11:45am CET, and it aimed to provide valuable insights on how innovative startups and visionary entrepreneurs are reshaping the healthcare landscape by using in silico technologies.
In this webinar, speakers whose career took them to start-ups, large companies, consultancy companies, focused on the convergence of technology, healthcare, and entrepreneurship through their experiences.
As always, the webinar included an interactive session for participants to ask questions to the speakers:
Sheena Macpherson is an entrepreneur with over 17 years’ experience within both multi-national companies and start-ups, specialising in regulated medical software. She is the CEO of adsilico, University of Leeds spin-out offering high-fidelity virtual populations suitable to assess safety, efficacy & performance of medical devices within in silico trials.
Matthieu De Beule is co-founder and CEO of FEops - a digital health leader in personalized predictive planning for structural heart interventions. Enabling manufacturers and assisting physicians to optimize structural heart interventions
Philippe Favre is an Associate Director at Zimmer Biomet, based in Switzerland, leading the computational biomechanics group. This group performs all simulations in support of implant development, and leads several research projects, including the development of an in silico clinical trial. He obtained his Master in mechanical engineering from the EPFL and his PhD from the ETHZ.
François-Henri Boissel holds an MSc in Management from ESSEC Business School. Prior to founding NOVA, he spent four years with investment bank Lehman Brothers in London and Tokyo where he has developed an expertise in financial engineering, deal structuring & execution. He has participated in securitization deals across a wide range of assets representing total completed financings in excess of $500 million USD in Europe and Asia. As NOVA’s cofounder and CEO since 2010, he has honed a variety of skills ranging from corporate structuring to business development and people management.
Luca Emili is the founder and CEO of InSilicoTrials Technologies, a platform facilitating the use of modeling and simulation in healthcare and life sciences. Prior to this, he was the CEO of Emaze, a cybersecurity firm that specialized in automated security analysis for complex networks. He is actively involved in several advisory roles, including the Cloud Security Consultative Group at EMA, and coordinates the Research Collaboration Agreement between InSilicoTrials and the FDA.
